The Effect and safety Assessment of Metformin Therapy in Growth Hormone-secreting Pituitary Adenoma (GH-PA) Patients who inoperable or incomplete control after surgery The Effect and safety Assessment of Metformin Therapy in Growth Hormone-secreting Pituitary Adenoma ...
The Effect and safety Assessment of Metformin Therapy in Growth Hormone-secreting Pituitary Adenoma (GH-PA) Patients who inoperable or incomplete control after surgery The Effect and safety Assessment of Metformin Therapy in Growth Hormone-secreting Pituitary Adenoma ...
Bromocentine Group:bromocentine mesylate tablet, starting dose is 0.625-1.25mg/d and the weekly increase of 1.25mg/d until 10-15mg/d.;Bromocentine and Metformin Group:metformin hydrochloride enteric solution 0.5g three times a day added on the basis of bromocentine mesylate tablet;Gamma Knife Radiosurgery Group:Gamma Knife Radiosurgery;Gamma Knife Radiosurgery and Metformin Group:metformin hydrochloride enteric solution 0.5g three times a day added on the basis of gamma knife radiosurgery; Bromocentine Group:bromocentine mesylate tablet, starting dose is 0.625-1.25mg/d and the weekly incr ...
Department of Endocrinology, Second Affiliated Hospital of Army Medical University
NULL
Pending
18
70
Both
Bromocentine Group:10;Bromocentine and Metformin Group:10;Gamma Knife Radiosurgery Group:10;Gamma Knife Radiosurgery and Metformin Group:10;